Floatz logo

rtx001

Chronic Liver Failure

Resolution Therapeutics LimitedCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Chronic Liver Failure cohort.

Asset / SponsorPhaseRating
Angiotensin Ii
University of California, Los Angeles
Phase 4BB
Noradrenaline
University of California, Los Angeles
Phase 4BB
Serostim
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 2/3B
Sofosbuvir
Gilead Sciences
Phase 2B
Ribavirin
Gilead Sciences
Phase 2B

View all 10 →

Same molecule, other indications

rtx001 is also rated in:

fatty liver diseaseActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
cirrhosis of liverActive
CC
Indicative · Phase 1/2
47 / 100
View asset →
liver disorderActive
CC
Indicative · Phase 1/2
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →